INTEGRA LIFESCIENCES HOLDINGS CORP (IART)
Health Care · medical devices · NASDAQ
A global medical technology leader specializing in neurosurgery and regenerative tissue reconstruction.
What INTEGRA LIFESCIENCES HOLDINGS CORP does
Integra LifeSciences is a global medical technology company that develops and manufactures products for neurosurgery, tissue reconstruction, and surgical instrumentation. It operates through two primary segments: Specialty Surgery, which provides technologies for neurosurgery, neurocritical care, and ENT procedures, and Tissue Reconstruction, which focuses on wound reconstruction solutions. The company is a leader in regenerative technology, including dermal repair and dural substitutes for brain surgery.
Recent developments
The company is managing a July 2026 flooding event at its Cincinnati manufacturing facility, which has caused operational disruptions and negatively impacted third-quarter and full-year 2026 revenue guidance. Full-year 2026 revenue and adjusted EPS outlooks were lowered, with a full return to manufacturing at the site not expected until the second quarter of 2027.
From INTEGRA LIFESCIENCES HOLDINGS CORP's filing of 2026-10-02.
Themes: neurosurgery, regenerative medicine, surgical instrumentation, wound care, ENT (ear, nose, and throat)
Fundamentals
- Price$13.41 as of 2026-10-08 close
- Market cap$1.0B as of 2026-07-28 (share count; price 2026-10-08)
- 1-year return-9.5% 2025-10-08 close $14.81 → 2026-10-08 close $13.41
- P/En/a negative earnings
- Net margin-31.6% FY2025, SEC XBRL
- ROE-49.5% FY2025, SEC XBRL
- Debt / equity1.79 as of 2026-09-03
- Revenue growth (YoY)+1.6% as of 2026-09-03
- Revenue CAGR (3y)+1.6% SEC XBRL
- Beta1.38 as of 2026-09-03
- Last reported earnings2026-10-02 SEC EDGAR Form 8-K (Item 2.02)
How IART compares in its sector
- net profit marginmiddle range 430 covered Health Care peers, as of 2026-09-03
- operating marginmiddle range 417 covered Health Care peers, as of 2026-09-03
- return on equitymiddle range 510 covered Health Care peers, as of 2026-09-03
- 3-year revenue CAGRmiddle range 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)middle range 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How INTEGRA LIFESCIENCES HOLDINGS CORP looks technically
INTEGRA LIFESCIENCES HOLDINGS CORP (IART) is trading 4.3% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed above its 200-day average about 83 trading days ago — a "golden cross", a bullish long-term signal. A trend is forming but not yet strong — ADX, a 0–100 trend-strength gauge, is 24 (a reading of 25+ marks a strong trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 35, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bearish about 5 trading days ago (its momentum flipped negative). It made a new 20-day low about 5 trading days ago. It is 34.6% below its highest point of the past year.
Trend
8
| Distance from the 200-day | it is trading 4.3% below its 200-day average, the long-term trend line — a long-term downtrend | -4.3% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $16.30 | $16.30 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $14.01 | $14.01 |
| Swing structure | each recent peak has been lower than the one before it and each dip deeper — the pattern chart-watchers call a downtrend, which describes where price has already been and not where it goes next | lower highs and lower lows |
| Last swing turn | its last significant turn was a swing high 9 calendar days ago — the swings before that are what the structure reading is measured on | 9 sessions |
| Wave structure | its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five; the labelling fails if price closes above 16.77. It is one of several labellings that fit, and it describes the swings already printed, not what comes next. The same swings also read as a three-part correction in leg C. | possible downward five-wave sequence, in wave 3 (one of several readings) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 83 trading days ago — a "golden cross", a bullish long-term signal | 83 sessions |
| Trend strength (14-day ADX) | a trend is forming but not yet strong — ADX, a 0–100 trend-strength gauge, is 24 (a reading of 25+ marks a strong trend) | 24.4 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 35, neither overbought (above 70) nor oversold (below 30) | 35.0 |
|---|---|---|
| Position in its 14-day range | it is trading in the lower half of its 14-day range ($12.35 to $16.77) — its "stochastic" reading is 24 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 24.0 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bearish about 5 trading days ago (its momentum flipped negative) | 5 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $20.49 | $20.49 |
|---|---|---|
| From the 52-week high | it is 34.6% below its 52-week high (its highest price of the past year) | -34.5% |
| Above the 52-week low | it is 54.1% above its 52-week low (its lowest price of the past year) | +54.1% |
| Below the 52-week high | it is 34.6% below its highest point of the past year | 34.5% |
| Since a 20-day breakout | it made a new 20-day low about 5 trading days ago | 5 sessions |
| Since a 55-day breakout | it made a new 55-day low about 5 trading days ago | 5 sessions |
| All-time high | its highest closing price on record is $77.40 (set on 2021-04-28) | $77.40 |
| Given back of the 52-week move | over the past year its closes ranged ($8.90 to $19.85), and it has given back a bit over half of its rise from last year’s low — 59% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $12.73 to $13.08. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 58.8% |
| From the all-time high | it is 82.7% below its all-time high | -82.7% |
| Nearest price level | it is trading 4.9% above a support level at $12.75 — a price it turned at three times since 2025-09-29, most recently on 2025-12-10. Since 2024-10-08 it has 7 such levels below the current price and 10 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -4.9% |
| All-time low | its lowest closing price on record is $8.58 (set on 2009-03-09) | $8.58 |
| Above the all-time low | it is 56.4% above its all-time low | +56.4% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are unusually wide versus its own recent history (wider than about 85% of the past ~6 months) | 85th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.8257 between its high and its low — about 6.2% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.8257 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $12.71 and $17.63 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $12.71 – $15.17 – $17.63 |
| Typical daily range (% of price) | its price moves about 6.2% in a typical session — more volatile than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 6.2% |
| Stretch from the 200-day average | it is trading 0.7 daily ranges below its 200-day average price (4.3% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 0.7 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 1.49× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | not available for this company yet | n/a |
Candlestick patterns
2
| Since a hammer | 2 sessions ago, after a stretch of decline, it sold off hard during the session and then closed back near its high — a "hammer", the long lower wick showing the drop was bought back before the close | 2 sessions ago |
|---|---|---|
| Since a bullish engulfing | today it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | today |
Price gaps
3
| Gap at the open | it opened on 2026-10-08 1.1% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | -1.1% |
|---|---|---|
| Open gap | it gapped 17.3% below the previous close 4 sessions ago and has not traded back through the level it left behind at 16.09 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | -17.3% |
| Gap filled | a 3.4% gap up opened on 2026-09-11 has been "filled" 19 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 19 sessions ago |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 18.6 percentage points (the stock lost 17.5% while the market gained 1.0%) | -18.6% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 26.3 percentage points (the stock lost 22.5% while the market gained 3.8%) | -26.3% |
| vs market, 6 months | over the past 6 months this stock beat the market by 26.6 percentage points (the stock gained 44.0% while the market gained 17.5%) | +26.6% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 24.4 percentage points (the stock lost 9.5% while the market gained 15.0%) | -24.4% |
Signal agreement
2
| Bullish technical signals | 2 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, outperforming the market over 6 months — these describe past price behaviour, not a forecast | 2 of 9 |
|---|---|---|
| Bearish technical signals | 3 of the 9 technical signals we can compute for it are currently in a bearish state: trading below its 200-day average, MACD momentum is negative, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 3 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 24% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-01 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is moderate, spanning 5.2% of the share price. | -23.9% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 5% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $14.16 — a volume-weighted average of daily closes over 191 sessions, not a true tick-by-tick VWAP. | -5.3% |
|---|---|---|
| Vs the average paid since it last reported | the price is 15% below the average price paid since it last reported on 2026-07-29 (its 10-Q), so the typical buyer over that stretch is under water. That average is $15.86 — a volume-weighted average of daily closes over 51 sessions, not a true tick-by-tick VWAP. | -15.4% |
Price levels it has turned at before
IART last closed at $13.41 on 2026-10-08. Since 2024-10-08 it has turned at 7 prices below its last close and 10 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $12.75 | Support | 4.9% below the last close | turned there three times · 2025-09-29 to 2025-12-10 |
| $14.10 | Resistance | 5.1% above the last close | turned there twice · 2025-07-31 to 2026-01-08 |
| $14.40 | Resistance | 7.4% above the last close | turned there three times · 2025-04-21 to 2025-12-11 |
| $11.93 | Support | 11.0% below the last close | turned there three times · 2025-05-23 to 2026-01-05 |
| $14.93 | Resistance | 11.3% above the last close | turned there twice · 2025-10-06 to 2026-09-18 |
| $11.58 | Support | 13.7% below the last close | turned there four times · 2025-05-05 to 2026-04-17 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five.
This labelling fails — stops being a possible reading at all — if it closes above $16.77.
This is one of several labellings that fit the same swings, so treat it as a reading rather than the reading. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
On past moves of this shape the leg has usually ended somewhere between $10.68 and $13.01 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
Alternate reading: The same swings also read as a three-part correction in leg C, which fails on a close above $16.77.
This reading has stood for 3 trading days, since 2026-10-06.
Read from daily closes as of 2026-10-08.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Pulled back from the 12-month high · MACD just crossed bearish (12/26/9) · beating the market · Printed a bullish engulfing pair · Left an unfilled gap (5%+ in the last week) | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low
Based on daily closing prices as of 2026-10-08. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingHold (2.73 mean, 1=Strong Buy…5=Strong Sell) — 8 analysts
- Mean price target$18.38 range $14.00 – $27.00; median $16.00
Analyst estimates, as of 2026-10-09. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for IART
- Consensus EPS estimate$0.5646 next reporting period, as of 2026-10-09
- Estimate change, 30 days+$0.00124 (+0.2%) from $0.5634, on 2026-09-04, 35-day window
- Readings revised upward11% of 9 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Manufacturing disruptions, including recent flooding at the Cincinnati facility, which impact supply chains and revenue.","Stringent FDA and international regulatory scrutiny, including risks related to quality management systems, potential recalls, and product marketability.","Macroeconomic uncertainty impacting hospital procurement cycles, elective procedure volumes, and third-party reimbursement rates."]
What changed in the latest 10-Q
AI-assisted comparison of IART's 10-Q filed 2026-05-05 against the prior one filed 2025-10-30.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing references Annual Report on Form 10-K for year ended December 31, 2025 (vs. 2024 in older filing)
- Newer filing adds 'resources' to list of forward-looking statement topics
- Newer filing adds 'breaches, failures or other disruptions of our or our vendors' or customers' information technology systems or products' to risk factors
- Newer filing generalizes language about Braintree facility operationalization and removes specific product transition details
- Newer filing adds reference to 'increased geopolitical tension, instability' at beginning of risk factors list
- Removed:
- Older filing's specific references to 'transition of the manufacture of SurgiMend® and PriMatrix® to the Braintree facility' removed in newer filing
- Older filing's specific references to 'PMA of SurgiMend PRS in implant-based breast reconstruction and to obtain a PMA for Durasorb® in 2026' removed in newer filing
- Older filing's 'CMP implementation and engagement' changed to 'CMP implementation, engagement and efficacy' in newer filing
- Older filing's specific risk regarding 'building and the operationalization of the Braintree facility or the transition of manufacturing activities from the Company's Boston facility to the Braintree facility' removed in newer filing
- Older filing's detailed list including 'the Company's ability to successfully integrate acquired businesses', 'ability to achieve sales growth in a timely fashion', 'manage its direct sales channels effectively', 'sales performance of third-party distributors', 'access and maintain relationships with customers of acquired entities' largely removed or consolidated in newer filing
- Older filing's references to 'disruptions at the FDA', 'reduction in the FDA's and CMS' workforce', 'U.S. government shutdown which began in October 2025' removed in newer filing
- Older filing's language about 'scope, duration and effect of additional U.S. and international governmental, regulatory, fiscal, monetary and public health responses' removed in newer filing
- Reworded:
- Older filing's 'business strategy and plans, our growth and growth strategies, developments in the markets' consolidated to 'future business, operational and financial performance' in newer filing
- Older filing's 'our planned product launches and effectiveness' changed to 'product development, product availability' in newer filing
- Older filing's 'competitive strengths, objectives of management for future operations and current expectations or forecasts' removed and consolidated in newer filing
- Risk factors introduction changed from 'the ongoing and possible future effects of global challenges, including macroeconomic uncertainties, inflation, supply chain disruptions, trade regulation and tariffs, political instability, violent conflicts' to 'increased geopolitical tension, instability and other macroeconomic factors, including trade barriers and related restrictions (including tariffs and related countermeasures), armed conflict and acts of terrorism, supply chain disruptions' in newer filing
- Older filing's 'the Company's ability to execute its operating plan effectively' changed to 'the Company's ability to execute its financial, strategic and operating plans effectively' in newer filing
- Older filing's detailed manufacturing and distribution language consolidated to simpler version in newer filing
- Older filing's 'physicians' willingness to adopt and third-party payors' willingness to provide or maintain reimbursement' consolidated to 'the coverage and reimbursement decisions of third-party payors' in newer filing
- Newer filing generalizes CMP expectations language compared to older filing's specificity
- Notes:
- Both filings are partially truncated; comparison covers available text only
- Newer filing dated 2026-05-05 covers quarter ended March 31, 2026; older filing dated 2025-10-30 covers quarter ended September 30, 2025
- Some changes may reflect periodic updates typical between quarterly filings rather than material business changes
- Page numbers differ (33 vs. 38) suggesting document structure changes beyond MD&A section
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales are on record for IART — recent Form 4 activity was compensation-related (awards, option exercises, or tax withholding), not open-market buying or selling.
View full insider trading history → View SEC Form 3/4/5 filingsOnly open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
4 institutional 13F filers reported holding IART as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 4
- Reported shares held 13,646,606
- Reported value $245,093,036
reported quarterly holdings change (2026-03-31 → 2026-06-30): 1 new, 3 increased, 0 decreased, 1 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about IART's institutional holders → See what each manager we track holds →
Short interest (FINRA)
IART had 6,806,086 shares of reported short interest as of the 2026-09-15 FINRA settlement date (delayed, bi-monthly; not real-time).
IART had 8.75% of its shares outstanding sold short as of the 2026-09-15 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 8.26 days to cover at the same settlement.
- Reported short interest (shares) 6,806,086
- Short interest (% of shares outstanding) 8.75%
- Prior settlement (shares) 6,858,036
- Reported change -0.76%
- Days to cover (reported) 8.26
Reported to FINRA as of the 2026-09-15 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Medtronic (MDT)
- Stryker (SYK)
- Baxter International (BAX)
- Johnson & Johnson (JNJ)
- B. Braun Melsungen AG
- Conmed Corporation (CNMD)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare IART vs…
INTEGRA LIFESCIENCES HOLDINGS CORP is found in…
Frequently asked questions
What does INTEGRA LIFESCIENCES HOLDINGS CORP (IART) do?
Integra LifeSciences is a global medical technology company that develops and manufactures products for neurosurgery, tissue reconstruction, and surgical instrumentation. It operates through two primary segments: Specialty Surgery, which provides technologies for neurosurgery, neurocritical care, and ENT procedures, and Tissue Reconstruction, which focuses on wound reconstruction solutions.
What sector is INTEGRA LIFESCIENCES HOLDINGS CORP (IART) in?
INTEGRA LIFESCIENCES HOLDINGS CORP (IART) is classified in the Health Care sector. Its industry is medical devices. It trades on NASDAQ.
Who are INTEGRA LIFESCIENCES HOLDINGS CORP's (IART) competitors?
Notable peers of INTEGRA LIFESCIENCES HOLDINGS CORP (IART) include Medtronic, Stryker, Baxter International, Johnson & Johnson and B. Braun Melsungen AG. This peer set is informational only — not financial advice.
Is INTEGRA LIFESCIENCES HOLDINGS CORP (IART) overbought or oversold right now?
INTEGRA LIFESCIENCES HOLDINGS CORP (IART) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 35, in the neutral middle (as of 2026-10-08). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on IART come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest; prices are market data, as of 2026-09-03; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.